Aligos Therapeutics announces IND clearance for ALG-055009

Aligos Therapeutics has received clearance of its Investigational New Drug application from the US Food and Drug Administration for ALG-055009, it’s thyroid hormone receptor beta agonist, intended for the treatment of nonalcoholic steatohepatitis. The study is designed to evaluate the safety and efficacy of up to 4 dose levels of ALG-055009, compared to placebo, over a 12-week treatment period in presumed NASH patients. As is typical for studies at this phase of development, the study’s primary endpoint will be change in MRI-PDFF, which has been shown to correlate with liver histology with other THR-beta agonists in development.